Affordable Access

Access to the full text

Streamlined selection of cancer antigens for vaccine development through integrative multi-omics and high-content cell imaging

Authors
  • Han, Ki-Cheol1
  • Park, Daechan2
  • Ju, Shinyeong1
  • Lee, Young Eun1, 3
  • Heo, Sun-Hee4, 5
  • Kim, Young-Ae4
  • Lee, Ji Eun1
  • Lee, Yuna3
  • Park, Kyong Hwa6
  • Park, Se-Ho3
  • Lee, Hee Jin4, 5
  • Lee, Cheolju1, 7
  • Jang, Mihue1, 7
  • 1 Center for Theragnosis, Biomedical Research Institute, Korea Institute of Science and Technology, Seongbuk-Gu, Seoul, 02792, Republic of Korea , Seoul (South Korea)
  • 2 Ajou University, Suwon, 16499, Republic of Korea , Suwon (South Korea)
  • 3 Korea University, 145 Anam-ro, Seongbuk-gu, Seoul, 02841, Republic of Korea , Seoul (South Korea)
  • 4 University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul, 05505, Republic of Korea , Seoul (South Korea)
  • 5 University of Ulsan College of Medicine, Asan Medical Center, Seoul, 05505, Republic of Korea , Seoul (South Korea)
  • 6 Korea University College of medicine, Seongbuk-Gu, Seoul, 02841, Republic of Korea , Seoul (South Korea)
  • 7 KHU-KIST, Kyung Hee University, Seoul, 02447, Republic of Korea , Seoul (South Korea)
Type
Published Article
Journal
Scientific Reports
Publisher
Springer Nature
Publication Date
Apr 03, 2020
Volume
10
Issue
1
Identifiers
DOI: 10.1038/s41598-020-62244-z
Source
Springer Nature
License
Green

Abstract

Identification of tumor antigens that induce cytotoxic T lymphocytes (CTLs) is crucial for cancer-vaccine development. Despite their predictive ability, current algorithmic approaches and human leukocyte antigen (HLA)-peptidomic analysis allow limited selectivity. Here, we optimized a method to rapidly screen and identify highly immunogenic epitopes that trigger CTL responses. We used a combined application of this method involving immune-specific signature analysis and HLA-associated peptidomics using samples from six patients with triple-negative breast cancer (TNBC) in order to select immunogenic HLA epitopes for in vitro testing. Additionally, we applied high-throughput imaging at the single-cell level in order to confirm the immunoreactivity of the selected peptides. The results indicated that this method enabled identification of promising CTL peptides capable of inducing antitumor immunity. This platform combining high-resolution computational analysis, HLA-peptidomics, and high-throughput immunogenicity testing allowed rapid and robust identification of highly immunogenic epitopes and represents a powerful technique for cancer-vaccine development.

Report this publication

Statistics

Seen <100 times